IGC

IGC Pharma (IGC)

IGC Pharma Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:AMEX:IGC

1 2 3 4 5 6 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/04/16	20 : 00	Business Wire	IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two	AMEX:IGC	IGC Pharma Inc
2024/04/09	22 : 00	Business Wire	IGC Pharma Adds Advisor in Artificial Intelligence	AMEX:IGC	IGC Pharma Inc
2024/03/27	04 : 00	Business Wire	IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock	AMEX:IGC	IGC Pharma Inc
2024/03/21	00 : 00	Business Wire	IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation	AMEX:IGC	IGC Pharma Inc
2024/03/20	20 : 00	Business Wire	IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024	AMEX:IGC	IGC Pharma Inc
2024/03/13	04 : 00	Business Wire	IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline	AMEX:IGC	IGC Pharma Inc
2024/02/29	03 : 00	Business Wire	Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model	AMEX:IGC	IGC Pharma Inc
2024/02/24	02 : 01	Business Wire	IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target	AMEX:IGC	IGC Pharma Inc
2024/02/17	09 : 05	Business Wire	IGC Pharma Reports Third Quarter Fiscal 2024 Results	AMEX:IGC	IGC Pharma Inc
2024/02/15	06 : 03	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	AMEX:IGC	IGC Pharma Inc
2024/02/01	23 : 20	Business Wire	IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model	AMEX:IGC	IGC Pharma Inc
2024/02/01	06 : 04	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	AMEX:IGC	IGC Pharma Inc
2024/01/23	23 : 20	Business Wire	IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s	AMEX:IGC	IGC Pharma Inc
2024/01/17	23 : 20	Business Wire	IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial	AMEX:IGC	IGC Pharma Inc
2024/01/09	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	AMEX:IGC	IGC Pharma Inc
2023/12/30	06 : 54	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	AMEX:IGC	IGC Pharma Inc
2023/12/19	23 : 20	Business Wire	Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s	AMEX:IGC	IGC Pharma Inc
2023/12/13	23 : 30	Business Wire	IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024	AMEX:IGC	IGC Pharma Inc
2023/12/06	22 : 30	Business Wire	IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials	AMEX:IGC	IGC Pharma Inc
2023/11/21	22 : 30	Business Wire	IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives	AMEX:IGC	IGC Pharma Inc
2023/11/13	22 : 00	Business Wire	IGC Pharma Reports Second Quarter Fiscal 2024 Results	AMEX:IGC	IGC Pharma Inc
2023/11/10	07 : 15	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	AMEX:IGC	IGC Pharma Inc
2023/10/28	06 : 21	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:IGC	IGC Pharma Inc
2023/10/28	05 : 38	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	AMEX:IGC	IGC Pharma Inc
2023/10/20	04 : 30	Business Wire	IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy	AMEX:IGC	IGC Pharma Inc
2023/10/06	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	AMEX:IGC	IGC Pharma Inc
2023/09/30	06 : 23	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	AMEX:IGC	IGC Pharma Inc
2023/08/22	03 : 30	Business Wire	IGC Announces Results of its 2023 Annual Stockholders Meeting	AMEX:IGC	IGC Pharma Inc
2023/08/22	01 : 44	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:IGC	IGC Pharma Inc
2023/08/14	21 : 30	Business Wire	IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical Trials	AMEX:IGC	IGC Pharma Inc